Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMSNASDAQ:ANIPNASDAQ:IDYANASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AANIPANI Pharmaceuticals$66.98+1.4%$64.51$52.50▼$77.00$1.43B0.55312,546 shs215,811 shsIDYAIDEAYA Biosciences$21.78+1.7%$19.75$13.45▼$44.42$1.88B0.041.03 million shs926,350 shsKNSAKiniksa Pharmaceuticals International$29.06+1.2%$26.31$17.38▼$30.69$2.10B0.06518,381 shs655,828 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIPANI Pharmaceuticals+1.44%+5.73%+15.90%-0.28%+6.62%IDYAIDEAYA Biosciences+1.68%-0.64%+15.73%+24.89%-41.14%KNSAKiniksa Pharmaceuticals International+1.18%+3.97%+8.07%+27.68%+54.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANIPANI Pharmaceuticals3.6376 of 5 stars2.51.00.03.32.13.31.3IDYAIDEAYA Biosciences3.3812 of 5 stars3.52.00.04.40.01.70.0KNSAKiniksa Pharmaceuticals International3.2068 of 5 stars3.53.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AANIPANI Pharmaceuticals 3.00Buy$80.1319.63% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27149.19% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8033.52% UpsideCurrent Analyst Ratings BreakdownLatest ADMS, KNSA, IDYA, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49ANIPANI Pharmaceuticals$614.38M2.36$7.71 per share8.69$19.11 per share3.50IDYAIDEAYA Biosciences$7M272.50N/AN/A$12.25 per share1.78KNSAKiniksa Pharmaceuticals International$423.24M5.01N/AN/A$6.60 per share4.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.91N/A-3.12%21.35%7.52%8/5/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A116.24N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)Latest ADMS, KNSA, IDYA, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17ANIPANI Pharmaceuticals1.462.661.98IDYAIDEAYA BiosciencesN/A13.9213.92KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%ANIPANI Pharmaceuticals76.05%IDYAIDEAYA Biosciences98.29%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%ANIPANI Pharmaceuticals12.70%IDYAIDEAYA Biosciences2.50%KNSAKiniksa Pharmaceuticals International53.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableADMS, KNSA, IDYA, and ANIP HeadlinesRecent News About These CompaniesKiniksa Pharmaceuticals International PLC - KNSA | Barron'sJune 24 at 10:23 PM | barrons.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comEben Tessari Sells 17,300 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) StockJune 19, 2025 | insidertrades.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLCJune 19, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of StockJune 18, 2025 | marketbeat.comKiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing FastJune 16, 2025 | seekingalpha.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded by Wall Street Zen to "Buy" RatingJune 15, 2025 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% on Insider SellingJune 12, 2025 | marketbeat.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 12, 2025 | insidertrades.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comBarry D. Quart Sells 8,212 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comEben Tessari Sells 10,319 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart Sells 12,336 SharesJune 11, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 15,506 Shares of StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $1,374,231.42 in StockJune 11, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 12,462 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)June 10, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High - What's Next?June 9, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Raised by Wellington Management Group LLPJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsJune 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADMS, KNSA, IDYA, and ANIP Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.ANI Pharmaceuticals NASDAQ:ANIP$66.98 +0.95 (+1.44%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$66.98 0.00 (0.00%) As of 06/24/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.IDEAYA Biosciences NASDAQ:IDYA$21.78 +0.36 (+1.68%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$21.78 0.00 (0.00%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$29.06 +0.34 (+1.18%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$29.06 0.00 (-0.02%) As of 06/24/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
